Vertex says combo of Roche drugs, telaprevir shows promise in study

04/27/2009 | Bloomberg

Vertex Pharmaceuticals announced that the combination of its hepatitis C drug telaprevir with Roche Holding's Pegasys and Copegus eradicated signs of the virus and elicited sustained response in 52% of patients, compared with 14% of those who received Roche's medicines alone. The yearlong study observed 453 patients who either relapsed after or failed to respond to previous hepatitis C therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR